Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 11Colorectal Neoplasms 4Breast Neoplasms 3Solid Tumors 2Sarcoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Neuroendocrine Tumors 1Neoplasms 1Liver Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Glioblastoma 1Gallbladder Neoplasms 1Disease Progression 1Disease 1Clear-cell metastatic renal cell carcinoma 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1Advanced Adult Hepatocellular Carcinoma 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × tivozanib × Clear all
NCT01885949 2026-05-20

Tivozanib + Enzalutamide in Adv Prostate Cancer

Massachusetts General Hospital

Phase 2 Terminated
5 enrolled 8 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01834183 2013-06-19

Tivozanib + Gemcitabine in Metastatic RCC

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡